Quartiles of serum SepP concentration (mg/L)Continuous (per 1 mg/L)
<2.582.58-2.902.90-3.24≥3.24
Cases/controls (n)61/12153/12474/11959/127
Crude OR* (95% CI)1.000.84 (0.54, 1.33)1.22 (0.79, 1.88)0.91 (0.57, 1.44)0.85 (0.62, 1.17)
Adjusted OR (95% CI)1.000.83 (0.52, 1.33)1.07 (0.68, 1.88)0.83 (0.51, 1.33)0.77 (0.55, 1.07)
Excluding cases diagnosed during 1st year of follow-up (and matched controls)
Cases/controls (n)58/11650/11668/11558/118
Adjusted OR (95% CI)1.000.85 (0.53, 1.36)1.00 (0.63, 1.59)0.88 (0.54, 1.43)0.79 (0.56, 1.11)
High-grade prostate cancer
Cases/controls (n)25/4918/3428/4120/58
Adjusted OR (95% CI)1.000.98 (0.46, 2.06)1.13 (0.55, 2.29)0.57 (0.27, 1.22)0.62 (0.37, 1.05)
Low-grade prostate cancer
Cases/controls (n)33/6627/7137/6433/56
Adjusted OR (95% CI)1.000.75 (0.39, 1.44)1.08 (0.57, 2.04)1.07 (0.55, 2.11)0.89 (0.56, 1.42)
  • *Crude OR from conditional logistic regression stratified by matching factors (age group and time of recruitment).

  • Adjusted OR additionally adjusted for family history of prostate cancer, participation in PSA testing, smoking status, and vigorous physical activity.